Lost in the debate over how Medicare will negotiate drug prices, there's a concern by federal agencies about a metric used in determining a drug’s value. It's known as the Quality-Adjusted Life Year. There's bipartisan agreement in not using the term QALY, and “not even Medicare officials have signaled they want to use that approach.” What exactly are they talking about?
Human factors in North Pole efficiency, the cost-effectiveness of Christmas, would we see evolution differently if Darwin played Go, our friends the T-cell, and why it is difficult to separate economics from the form of government we choose.